So Invivo are issued consideration shares at 21.5 cents each but shareholders were asked to pay 23 cents.
As stated earlier this acquisition is turning out to be a huge cost to longer term shareholders. The share price is now down 50% from when they announced the acquisition.
The company is being run by bankers and scientists. Not a good mix.
Hopefully the quarterly will be more positive than the previous quarterlies.
Ann: Application for quotation of securities - MAP, page-2
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
-0.005(2.70%) |
Mkt cap ! $80.61M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 17.5¢ | $14.56K | 82.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45827 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 126350 | 2 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| MAP (ASX) Chart |